BioSpace News Archive

Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday, December 14, 2021.

December 7, 2021
·
4 min read
Deals

Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve Replacement

Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatment company on December 7th, 2021.

December 7, 2021
·
6 min read
Deals

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering

Cingulate Inc. (“Cingulate” or the “Company”), today announced the pricing of its initial public offering of 4,166,666 shares of common stock and accompanying warrants to purchase 4,166,666 shares of common stock.

December 7, 2021
·
4 min read
Development of Cost-Effective and Sensitive Microfluidic-based Point-of-Care Devices to Fuel Revenue Growth of Microfluidics Market: Reports and Data

The global microfluidics market size is expected to reach USD 35.23 billion by 2028 at a CAGR of 11.8% according to a new report by Reports and Data. Microfluidics has been used in the study of antibiotic-resistant bacteria, nanoparticle transport in blood, and chemical reaction kinetics, to name a few.

December 7, 2021
·
7 min read
Job Trends

MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology’s Monoclonal Antibody Treatment for Patients with COVID‑19

Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection.

December 7, 2021
·
1 min read
Biotech Bay

Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter

Biotricity, Inc. has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development.

December 7, 2021
·
4 min read
Biotech Beach

Immunicom Announces Promising Preliminary Data from its Immunopheresis® Study in Late-Stage Cancer and Metastatic Melanoma Patients Presented at 2021 SITC Congress

Immunicom Announces Promising Preliminary Data from its Immunopheresis ® Study in Late-Stage Cancer and Metastatic Melanoma Patients Presented at 2021 SITC Congress.

December 7, 2021
·
8 min read
Pharm Country

Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting

Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII, including as monotherapy and early add-on therapy for focal and generalized seizures at the 2021 American Epilepsy Society (AES) Annual Meeting.

December 7, 2021
·
31 min read
Drug Development

Effort to repeat key cancer biology experiments reveals challenges and opportunities to improve replicability

A large-scale systematic investigation to replicate high-impact, preclinical cancer biology experiments identified barriers to conducting replications and observed weaker evidence for the findings compared with the original experiments.

December 7, 2021
·
8 min read
FDA

Saol Therapeutics Announces FDA Approval of LYVISPAH™ (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio

Saol Therapeutics announces the approval of LYVISPAH™ (baclofen) oral granules.

December 7, 2021
·
14 min read